Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 1491405, 14 pages
https://doi.org/10.1155/2017/1491405
Research Article

Dyslipidemia rather than Type 2 Diabetes Mellitus or Chronic Periodontitis Affects the Systemic Expression of Pro- and Anti-Inflammatory Genes

1Department of Morphology, School of Dentistry at Araraquara, São Paulo State University (UNESP), 14801-903 Araraquara, SP, Brazil
2Department of Diagnosis and Surgery, School of Dentistry at Araraquara, São Paulo State University (UNESP), 14801-903 Araraquara, SP, Brazil
3Postgraduate Program in Sciences of the University of Franca, 14404-600 Franca, SP, Brazil
4Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14040-900 Ribeirão Preto, SP, Brazil
5Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo (USP), 14040-900 Ribeirão Preto, SP, Brazil

Correspondence should be addressed to Rafael Nepomuceno; moc.liamg@onecumopenleafar and Raquel Mantuaneli Scarel-Caminaga; rb.psenu.raof@leuqar

Received 8 September 2016; Accepted 26 January 2017; Published 20 February 2017

Academic Editor: Anshu Agrawal

Copyright © 2017 Rafael Nepomuceno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. M. Andriankaja, J. Galicia, G. Dong, W. Xiao, F. Alawi, and D. T. Graves, “Gene expression dynamics during diabetic periodontitis,” Journal of Dental Research, vol. 91, no. 12, pp. 1160–1165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010. View at Google Scholar
  3. A. D. Mooradian, “Dyslipidemia in type 2 diabetes mellitus,” Nature Clinical Practice Endocrinology & Metabolism, vol. 5, no. 3, pp. 150–159, 2009. View at Publisher · View at Google Scholar
  4. K. R. Feingold and M. D. Siperstein, “Diabetic vascular disease,” Advances in Internal Medicine, vol. 31, pp. 309–340, 1986. View at Google Scholar · View at Scopus
  5. J. A. Farmer, “Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials,” Current Diabetes Reports, vol. 8, no. 1, pp. 71–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. P. Solano and R. B. Goldberg, “Management of dyslipidemia in diabetes,” Cardiology in Review, vol. 14, no. 3, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Wu and K. G. Parhofer, “Diabetic dyslipidemia,” Metabolism: Clinical and Experimental, vol. 63, no. 12, pp. 1469–1479, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-B. Lee, H.-Y. Yi, and K.-H. Bae, “The association between periodontitis and dyslipidemia based on the fourth Korea National Health and Nutrition Examination Survey,” Journal of Clinical Periodontology, vol. 40, no. 5, pp. 437–442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. C. Armitage, “Development of a classification system for periodontal diseases and conditions,” Northwest dentistry, vol. 79, 2000. View at Google Scholar · View at Scopus
  10. W. E. Moore and L. V. Moore, “The bacteria of periodontal diseases,” Periodontology 2000, vol. 5, article 66, 1994. View at Google Scholar
  11. R. C. Page and K. S. Kornman, “The pathogenesis of human periodontitis: an introduction.,” Periodontology 2000, vol. 14, pp. 9–11, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. J. L. Ebersole, D. Cappelli, G. Mott, L. Kesavalu, S. C. Holt, and R. E. Singer, “Systemic manifestations of periodontitis in the non-human primate,” Journal of Periodontal Research, vol. 34, no. 7, pp. 358–362, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Awartani and F. Atassi, “Evaluation of periodontal status in subjects with hyperlipidemia,” Journal of Contemporary Dental Practice, vol. 11, no. 2, pp. 33–40, 2010. View at Google Scholar · View at Scopus
  14. B. Chee, B. Park, and P. M. Bartold, “Periodontitis and type II diabetes: a two-way relationship,” International Journal of Evidence-Based Healthcare, vol. 11, no. 4, pp. 317–329, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. P. M. Preshaw, A. L. Alba, D. Herrera et al., “Periodontitis and diabetes: a two-way relationship,” Diabetologia, vol. 55, pp. 21–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Loe, “Periodontal disease: the sixth complication of diabetes mellitus,” Diabetes Care, vol. 16, no. 1, pp. 329–334, 1993. View at Publisher · View at Google Scholar · View at Scopus
  17. H. K. Lu and P. C. Yang, “Cross-Sectional analysis of different variables of patients with non-insulin dependent diabetes and their periodontal status,” International Journal of Periodontics and Restorative Dentistry, vol. 24, no. 1, pp. 71–79, 2004. View at Google Scholar · View at Scopus
  18. B. L. Mealey and T. W. Oates, “Diabetes mellitus and periodontal diseases,” Journal of Periodontology, vol. 77, no. 8, pp. 1289–1303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. P. N. Papapanou, “Periodontal diseases: epidemiology,” Annals of periodontology, vol. 1, no. 1, pp. 1–36, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Bullon, J. M. Morillo, M. C. Ramirez-Tortosa, J. L. Quiles, H. N. Newman, and M. Battino, “Metabolic syndrome and periodontitis: is oxidative stress a common link?” Journal of Dental Research, vol. 88, no. 6, pp. 503–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Bastos, D. T. Graves, A. P. D. M. Loureiro et al., “Lipid peroxidation is associated with the severity of periodontal disease and local inflammatory markers in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 8, pp. E1353–E1362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. C. T. Corbi, A. S. Bastos, S. R. P. Orrico et al., “Elevated micronucleus frequency in patients with type 2 diabetes, dyslipidemia and periodontitis,” Mutagenesis, vol. 29, no. 6, pp. 433–439, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. R. J. L. Bondar and D. C. Mead, “Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum,” Clinical Chemistry, vol. 20, no. 5, pp. 586–590, 1974. View at Google Scholar · View at Scopus
  24. A. de Souza Bastos, D. T. Graves, A. P. de Melo Loureiro et al., “Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients,” Journal of Diabetes and Its Complications, vol. 30, no. 8, pp. 1593–1599, 2016. View at Publisher · View at Google Scholar
  25. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  26. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. “1999 International International Workshop for a Classification of Periodontal Diseases and Conditions. Papers. Oak Brook, Illinois, October 30–November 2, 1999,” Annals of Periodontology, vol. 4, no. 1, pp. i1–i112, 1999.
  28. P. A. Koromantzos, K. Makrilakis, X. Dereka, N. Katsilambros, I. A. Vrotsos, and P. N. Madianos, “A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with type 2 diabetes. Part I: effect on periodontal status and glycaemic control,” Journal of Clinical Periodontology, vol. 38, no. 2, pp. 142–147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. L. B. Cavalcante, M. H. Tanaka, J. R. Pires et al., “Expression of the interleukin-10 signaling pathway genes in individuals with down syndrome and periodontitis,” Journal of Periodontology, vol. 83, no. 7, pp. 926–935, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. H. Tanaka, E. M. A. Giro, L. B. Cavalcante et al., “Expression of interferon-γ, interferon-α and related genes in individuals with Down syndrome and periodontitis,” Cytokine, vol. 60, no. 3, pp. 875–881, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Bassols, P. Botas, J. M. Moreno-Navarrete et al., “Environmental and genetic factors influence the relationship between circulating il-10 and obesity phenotypes,” Obesity, vol. 18, no. 3, pp. 611–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Esposito, A. Pontillo, F. Giugliano et al., “Association of low interleukin-10 levels with the metabolic syndrome in obese women,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 3, pp. 1055–1058, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. N. Pham, M. I. Hawa, C. Pfleger et al., “Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4,” Diabetologia, vol. 54, no. 7, pp. 1630–1638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Watanabe, V. Grijalva, S. Hama et al., “Hemoglobin and its scavenger protein haptoglobin associate with ApoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein,” Journal of Biological Chemistry, vol. 284, no. 27, pp. 18292–18301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Liu, Y. J. Jia, X. L. Li et al., “Serum interleukin-10 levels and adverse events in patients with acute coronary syndrome: a systematic review and meta-analysis,” Chinese Medical Journal, vol. 127, no. 1, pp. 150–156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. García-Hernández, H. Arzate, I. Gil-Chavarría, R. Rojo, and L. Moreno-Fierros, “High glucose concentrations alter the biomineralization process in human osteoblastic cells,” Bone, vol. 50, no. 1, pp. 276–288, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. K. M. Choi, O. H. Ryu, K. W. Lee et al., “Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome,” Diabetes Research and Clinical Practice, vol. 75, no. 2, pp. 235–240, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Narverud, T. Ueland, M. S. Nenseter et al., “Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10,” Atherosclerosis, vol. 214, no. 1, pp. 163–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. E. van Exel, J. Gussekloo, A. J. M. De Craen, M. Frölich, A. B.-V. D. Wiel, and R. G. J. Westendorp, “Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-plus study,” Diabetes, vol. 51, no. 4, pp. 1088–1092, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Y. Jang, K.-S. Kim, C.-S. Park et al., “Exposure to hypergravity increases serum interleukin-5 and pulmonary infiltration in mice with allergic asthma,” Central European Journal of Immunology, vol. 39, no. 4, pp. 434–440, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. R. P. Donnelly, H. Dickensheets, and D. S. Finbloom, “The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes,” Journal of Interferon and Cytokine Research, vol. 19, no. 6, pp. 563–573, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. J. J. Senn, P. J. Klover, I. A. Nowak et al., “Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes,” The Journal of Biological Chemistry, vol. 278, no. 16, pp. 13740–13746, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Rieusset, K. Bouzakri, E. Chevillotte et al., “Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients,” Diabetes, vol. 53, no. 9, pp. 2232–2241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Ghanim, S. Abuaysheh, C. L. Sia et al., “Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance,” Diabetes Care, vol. 32, no. 12, pp. 2281–2287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Deopurkar, H. Ghanim, J. Friedman et al., “Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of toll-like receptor-4 and suppressor of cytokine signaling-3,” Diabetes Care, vol. 33, no. 5, pp. 991–997, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. E. C. Alexandropoulos, G. J. Kontochristopoulos, and N. Zakopoulou, “Hypertriglyceridaemia during low-dose interferon alpha-2b treatment in a patient with Kaposi's sarcoma,” Dermatology, vol. 202, no. 4, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Fernández-Miranda, G. Castellano, C. Guijarro et al., “Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α,” The American Journal of Gastroenterology, vol. 93, no. 10, pp. 1901–1904, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Sgarabotto, F. Vianello, P. M. Stefani et al., “Hypertriglyceridemia during long-term interferon-α therapy in a series of hematologic patients,” Journal of Interferon and Cytokine Research, vol. 17, no. 5, pp. 241–244, 1997. View at Google Scholar · View at Scopus
  49. E. Shinohara, S. Yamashita, S. Kihara et al., “Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C,” Hepatology, vol. 25, no. 6, pp. 1502–1506, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Levy, R. Rachmani, S. Trestman et al., “Low-dose interferon-α accelerates atherosclerosis in an LDL receptor-deficient mouse model,” European Journal of Internal Medicine, vol. 14, no. 8, pp. 479–483, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Grunfeld, M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold, “Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 5, pp. 1045–1052, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ito, P. Ansari, M. Sakatsume et al., “Interleukin-10 inhibits expression of both interferon α- and interferon γ-induced genes by suppressing tyrosine phosphorylation of STAT1,” Blood, vol. 93, no. 5, pp. 1456–1463, 1999. View at Google Scholar · View at Scopus
  53. M. J. Aman, T. Tretter, I. Eisenbeis et al., “Interferon-α stimulates production of interleukin-10 in activated CD4+ T cells and monocytes,” Blood, vol. 87, no. 11, pp. 4731–4736, 1996. View at Google Scholar · View at Scopus
  54. S. A. Huber, P. Sakkinen, C. David, M. K. Newell, and R. P. Tracy, “T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia,” Circulation, vol. 103, no. 21, pp. 2610–2616, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. S.-J. Lin, J.-Y. Wang, L. B. Klickstein et al., “Lack of age-associated LFA-1 up-regulation and impaired ICAM-1 binding in lymphocytes from patients with Down syndrome,” Clinical and Experimental Immunology, vol. 126, no. 1, pp. 54–63, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. Y.-C. Lin, M.-C. Lu, C. Lin et al., “Activation of IFN-γ/STAT/IRF-1 in hepatic responses to Klebsiella pneumoniae infection,” PLoS ONE, vol. 8, no. 11, Article ID e79961, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. N. E. Street and T. R. Mosmann, “Functional diversity of T lymphocytes due to secretion of different cytokine patterns,” FASEB Journal, vol. 5, no. 2, pp. 171–177, 1991. View at Google Scholar · View at Scopus
  58. R. T. Gazzinelli, I. P. Oswald, S. L. James, and A. Sher, “IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages,” Journal of Immunology, vol. 148, no. 6, pp. 1792–1796, 1992. View at Google Scholar · View at Scopus
  59. P. Ralph, I. Nakoinz, A. Sampson-Johannes et al., “IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor,” Journal of Immunology, vol. 148, no. 3, pp. 808–814, 1992. View at Google Scholar · View at Scopus
  60. A. D'Andrea, M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri, “Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells,” Journal of Experimental Medicine, vol. 178, no. 3, article 1041, 1993. View at Publisher · View at Google Scholar · View at Scopus
  61. J. C. Wherry, R. D. Schreiber, and E. R. Unanue, “Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli,” Infection and Immunity, vol. 59, no. 5, pp. 1709–1715, 1991. View at Google Scholar · View at Scopus
  62. B. Okopień, R. Krysiak, J. Kowalski et al., “The effect of statins and fibrates on interferon-γ and interleukin-2 release in patients with primary type II dyslipidemia,” Atherosclerosis, vol. 176, no. 2, pp. 327–335, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. H. W. Murray, “Interferon-gamma, the activated macrophage, and host defense against microbial challenge,” Annals of Internal Medicine, vol. 108, no. 4, pp. 595–608, 1988. View at Publisher · View at Google Scholar · View at Scopus
  64. A.-K. L. Robertson, X. Zhou, B. Strandvik, and G. K. Hansson, “Severe hypercholesterolaemia leads to strong Th2 responses to an exogenous antigen,” Scandinavian Journal of Immunology, vol. 59, no. 3, pp. 285–293, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Lachmandas, F. Vrieling, L. G. Wilson et al., “The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with mycobacterium tuberculosis,” PLoS ONE, vol. 10, no. 2, Article ID e0117941, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. N. P. Kumar, R. Sridhar, V. V. Banurekha et al., “Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines,” Annals of the American Thoracic Society, vol. 10, no. 5, pp. 441–449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. K. S. Tan, K. O. Lee, K. C. Low et al., “Glutathione deficiency in type 2 diabetes impairs cytokine responses and control of intracellular bacteria,” The Journal of Clinical Investigation, vol. 122, no. 6, pp. 2289–2300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Ogbera, A. Azenabor, O. A. Ogundahunsi, A. O. Ekun, and E. N. Adejumo, “Cytokines, Type 2 DM and the Metabolic Syndrome,” Nigerian quarterly journal of hospital medicine, vol. 23, no. 4, pp. 318–322, 2013. View at Google Scholar · View at Scopus
  69. S. J. Burke, M. R. Goff, D. Lu, D. Proud, M. D. Karlstad, and J. J. Collier, “Synergistic expression of the CXCL10 gene in response to IL-1β and IFN-γ involves NF-κB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4,” Journal of Immunology, vol. 191, no. 1, pp. 323–336, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Schmid, M. Bala, S. Leszczak, I. Ober, C. Buechler, and T. Karrasch, “Pro-inflammatory chemokines CCL2, chemerin, IP-10 and RANTES in human serum during an oral lipid tolerance test,” Cytokine, vol. 80, pp. 56–63, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Dallmeier, M. G. Larson, R. S. Vasan et al., “Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study,” Diabetology and Metabolic Syndrome, vol. 4, no. 1, article 28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Flodström and D. L. Eizirik, “Interferon-γ-induced interferon regulatory factor-1 (IRF-1) expression in rodent and human islet cells precedes nitric oxide production,” Endocrinology, vol. 138, no. 7, pp. 2747–2753, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Tamura, H. Yanai, D. Savitsky, and T. Taniguchi, “The IRF family transcription factors in immunity and oncogenesis,” Annual Review of Immunology, vol. 26, pp. 535–584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Taniguchi, K. Ogasawara, A. Takaoka, and N. Tanaka, “IRF family of transcription factors as regulators of host defense,” Annual Review of Immunology, vol. 19, pp. 623–655, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Doly, A. Civas, S. Navarro, and G. Uze, “Type I interferons: expression and signalization,” Cellular and Molecular Life Sciences, vol. 54, no. 10, pp. 1109–1121, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Lehtonen, S. Matikainen, and I. Julkunen, “Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages,” The Journal of Immunology, vol. 159, no. 2, pp. 794–803, 1997. View at Google Scholar · View at Scopus
  78. A. Lehtonen, R. Lund, R. Lahesmaa, I. Julkunen, T. Sareneva, and S. Matikainen, “IFN-α and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells,” Cytokine, vol. 24, no. 3, pp. 81–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. O. Fentoglu and F. Y. Bozkurt, “The bi-directional relationship between periodontal disease and hyperlipidemia,” European Journal of Dentistry, vol. 2, pp. 142–146, 2008. View at Google Scholar